Treatment-Resistant Depression: Evidence-Based Management

Definition and Diagnostic Confirmation

The American Psychiatric Association defines treatment-resistant depression (TRD) as failure to respond (<50% reduction in symptom severity) to at least two adequate antidepressant trials with different mechanisms of action at minimum effective dosage for at least 4 weeks duration in the current depressive episode, as stated by the Molecular Psychiatry journal 1
A minimum of 2 failed adequate trials is the consensus standard for diagnosing TRD, though 48% of published studies use only 1 failed trial as entry criteria, according to Depression and Anxiety 3, 1
Each trial must be at therapeutic dose for ≥4 weeks minimum to be considered a failed trial, as recommended by Praxis Medical Insights 2, 4
Discontinuation due to side effects before 4 weeks does not count as treatment failure for establishing TRD, as stated by Praxis Medical Insights 2
For prolonged episodes, only failures within the last 2 years should be considered when diagnosing TRD, according to Praxis Medical Insights 2
Partial response (PRD) is defined as 25-50% symptom reduction, while TRD shows <25% reduction, as defined by Molecular Psychiatry 1, 5

The primary first-line FDA-approved strategy for treating TRD is augmentation with atypical antipsychotics (aripiprazole, quetiapine, olanzapine-fluoxetine combination), with the most extensive evidence base, as recommended by Praxis Medical Insights 2, 6
Aripiprazole augmentation is the first medication specifically FDA-approved for adjunctive treatment of TRD, as stated by Praxis Medical Insights 6
Olanzapine-fluoxetine combination is an FDA-approved option, starting with 5mg olanzapine and 20mg fluoxetine once daily in the evening, with a dose range of 5-20mg olanzapine and 20-50mg fluoxetine, as recommended by Praxis Medical Insights 6
Quetiapine augmentation is also FDA-approved for TRD, as stated by Praxis Medical Insights 6
Metabolic monitoring (weight, glucose, lipids) is required when using atypical antipsychotics, particularly olanzapine, as recommended by Praxis Medical Insights 6
Alternative first-line augmentation strategies include lithium augmentation, bupropion combination, liothyronine (T3) augmentation, lamotrigine, and tricyclic or mirtazapine combination, as recommended by Praxis Medical Insights 4, 6
Gabapentin is not recommended for TRD, as stated by Praxis Medical Insights 4

Esketamine or ketamine should be reserved for highly refractory cases who have failed multiple augmentation strategies, as recommended by Praxis Medical Insights 2, 6
Transcranial Magnetic Stimulation (TMS) should be considered for patients who have failed medication trials, particularly when medication side effects limit options, as recommended by Praxis Medical Insights 2
Electroconvulsive Therapy (ECT) remains an option for severe, refractory cases, though specific criteria vary, as stated by Depression and Anxiety 3

Cognitive behavioral therapy should be used in conjunction with pharmacotherapy, not as monotherapy in confirmed TRD, as recommended by Praxis Medical Insights 2

Depressive symptom severity should be tracked using standardized tools such as HAM-D or MADRS, as recommended by Depression and Anxiety and Praxis Medical Insights 3, 4
General psychiatric status should be monitored using the Clinical Global Impression scale, as recommended by Depression and Anxiety 3
Functional impairment and quality of life should be monitored, as recommended by Praxis Medical Insights 4
Suicidality reduction should be monitored, as recommended by Praxis Medical Insights 4
Medication adherence should be monitored, as recommended by Praxis Medical Insights 4
The goal of treatment is remission (complete symptom resolution), not just response, as stated by Depression and Anxiety and Depression and Anxiety 3, 7

Patients should not be excluded from treatment trials based solely on the number of prior failures, as recommended by Praxis Medical Insights 2, 4
Medication discontinuation due to side effects before 4 weeks should not be counted as treatment failure, as stated by Praxis Medical Insights 2
Bipolar depression should not be overlooked, as it requires mood stabilizers as foundation, not antidepressants alone, as recommended by Praxis Medical Insights 4
Drug interactions, particularly with fluoxetine's long half-life and CYP450 inhibition, should not be ignored, as recommended by Praxis Medical Insights 6